Scand J Infect Dis. 2013;45(4):315-9.
Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
제1저자 김낙현 · 교신저자 박완범
소속 (1)
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract
Although tigecycline is considered one of the few therapeutic options for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteraemia, its role in the treatment of CRAB bacteraemia remains unclear. We describe the clinical outcomes of 9 patients who received tigecycline for CRAB bacteraemia. Although all CRAB blood isolates were susceptible to tigecycline, 5 (56%) deaths were related to CRAB bacteraemia and 1 case of breakthrough CRAB bacteraemia was observed during tigecycline therapy. Clinical outcomes of tigecycline therapy may be poor in patients with tigecycline-susceptible CRAB bacteraemia, although multiple factors including delayed treatment could contribute to the poor outcomes.
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- Scandinavian journal of infectious diseases · eISSN 1651-1980
- 전자 출판
- 2012-10-31
- MeSH
- Acinetobacter Infections / drug therapy / microbiology · Acinetobacter baumannii / drug effects / isolation & purification · Adult · Aged · Aged, 80 and over · Anti-Bacterial Agents / therapeutic use · Bacteremia / drug therapy / microbiology · Cohort Studies · Drug Resistance, Multiple, Bacterial · Female · Humans · Male · Microbial Sensitivity Tests · Middle Aged · Minocycline / analogs & derivatives / therapeutic use · Tigecycline · Treatment Outcome · beta-Lactam Resistance
- Substances
- Anti-Bacterial Agents · Tigecycline · Minocycline